Bart Van Aarnhem joined Lonza in 2016 and currently serves as lead counsel for the Lonza Small Molecules division, covering drug substance and drug product. In addition to this, Bart is also lead counsel for Lonza’s Conjugation business unit. Bart received his Masters in Law from Leiden University in Holland.

David Lyon serves as a Senior Fellow, Global R&D, at Lonza's site in Bend, Oregon, USA, where he advises on internal and external collaborations for bioavailability enhancement technologies, modified release, and bioprocessing. David joined Bend Research as a Research Chemist in 1991. During his tenure at Bend Research, he held positions of increasing responsibility, leading numerous large-scale research programs and ultimately being named Senior Vice President, Research prior to the company’s acquisition by Capsugel and, subsequently, Lonza. His areas of expertise include extensive work with amorphous solid dispersions for bioavailability enhancement of active compounds with low aqueous solubility, as well as the development of modified release formulations and bioprocesses. David received his Bachelor of Science degree in Chemistry from Western Washington University and his Ph.D. in Inorganic Chemistry from the University of Oregon. Subsequently, he completed postdoctoral work at the California Institute of Technology.

Charles Johnson is currently working as Senior Director, Commercial Development at Lonza Small Molecules. Charles has over 20 years’ experience in the pharmaceutical sector and specializes in Antibody Drug Conjugates. Prior to joining Lonza, Charles was CEO of ADC Biotechnology which focuses on innovative immobilization technologies for protein conjugation and purification applications.

Cora Li is the Head of Quality, overseeing Quality Assurance (QA) and Quality Control (QC) at the Nansha (CN) site for Lonza Small Molecules. With a focus on quality management, Cora is dedicated to providing faster and smarter services to customers while ensuring compliance and high-quality standards. She has successfully supported customers in filing their products in various markets, including Japan, USA, EMEA, and ongoing efforts in China. Cora takes pride in the transparent communication and close collaboration with customers, acknowledging the impact their products have in saving lives.

Gemma Zuend is the Director of Program Management in the Small Molecules Division at Lonza. With a strong focus on customer satisfaction, Gemma and her diverse team work to ensure that customers receive the products and services they need. With a background in the pharmaceutical industry, Gemma was impressed by Lonza's expertise and breadth of services, leading her to join the company in Visp. She emphasizes the importance of customer involvement throughout the entire process, including regulatory submissions. Gemma's flexibility and dedication are exemplified through her work with small biotech companies, supporting them from initial batches to FDA acceptance. She believes in fostering positive experiences by maintaining clear communication with customers.